Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208

Published: Tuesday, October 08, 2013
Last Updated: Tuesday, October 08, 2013
Bookmark and Share
Extended treatment resulted in higher overall response rate.

MorphoSys AG and US-based Xencor, Inc. have announced completion of the phase 1/2a clinical trial evaluating MOR208 (formerly XmAb®5574) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL/SLL).

Safety and objective response data following the protocol defined 8-week treatment period was presented at the American Society of Hematology Annual Meeting in December 2012.

Due to signs of activity of MOR208 in this difficult to treat patient population, the study protocol was amended to allow those patients in the highest dose group benefitting from the treatment to enter a prolonged treatment group.

The final study results including the extended treatment arm showed an overall response rate of 29.6% (according to IWCLL 2008 criteria) based on the safety population of the trial (n=27) - up from the previously reported 14.8%. A detailed analysis of the study results will be published in a peer-reviewed scientific journal.

"We are very pleased with the outcome of the study including the cases of improved objective response in the extended treatment arm which underscores the excellent prospects of MOR208. The final data from this trial clearly demonstrate the drug's potential in chronic lymphocytic leukemia. MorphoSys is currently evaluating MOR208 in phase 2 clinical trials for NHL and B-ALL. An additional phase 2 combination study for MOR208 in chronic lymphocytic leukemia is an option we are looking at, too," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG.

The phase 1/2a trial was designed to assess the drug's safety, tolerability, pharmacokinetic profile and preliminary anti-tumor activity.

MOR208 was administered as an intravenous infusion on days 1, 4, 8, 15, and 22 of cycle 1, and on days 1, 8, 15, and 22 of cycle 2.

Dose levels tested ranged from 0.3 to 12 mg/kg. Clinical responses were assessed according to International Working Group on CLL (IWCLL) Guidelines. Eight patients qualified for the extended treatment group and received up to four additional treatment cycles with MOR208 including prolonged additional disease response assessments.

"The overall response rate of MOR208 demonstrates the drug's potential as a novel immunotherapy for B-cell malignancies", commented the principal investigator of the study John C. Byrd, MD, Professor and D. Warren Brown Chair of Leukemia Research at The James Cancer Hospital and Solove Research Institute. "The favorable safety profile of the antibody is another beneficial aspect, especially in heavily pre-treated patient population."

"The promising response rate of MOR208 in a relapsed or refractory patient group demonstrates the positive impact Fc engineering had on the antibody's activity against tumors. Currently, MOR208 is the most advanced of four programs Xencor's partners have in clinical development in oncology," commented Bassil Dahiyat, Ph.D., Chief Executive Officer of Xencor.

In June 2010, MorphoSys AG and Xencor signed a worldwide exclusive license and collaboration agreement. The agreement provided MorphoSys with an exclusive worldwide license to MOR208 for the treatment of cancer and other indications.

Using Xencor's XmAb® Fc enhancement technology, MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

After the successful completion of the phase 1/2a study in CLL MorphoSys is now solely responsible for further clinical development.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys to Receive Milestone Payment for Guselkumab Program
Company initiates phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody.
Tuesday, April 14, 2015
MorphoSys Nominates Three New Candidates for Supervisory Board
Company has nominated Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich.
Tuesday, March 31, 2015
MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration
MorphoSys regains rights to MOR202 antibody against CD38 and updates its financial guidance for 2015.
Friday, March 27, 2015
MorphoSys Provides Update on the Company's Proprietary Drug Portfolio
Early-stage portfolio now fully Ylanthia-based, includes programs with Merck Serono as well as first anti-GPCR programs.
Tuesday, July 29, 2014
MorphoSys Strengthens Clinical Development Organization with Three Management Appointments
Appointment of Dr. Gabriele Elbl, Dr. Ludger Langer and Dr. Steffen Heeger.
Monday, December 23, 2013
MorphoSys Announces Additional Clinical Trial of MOR208
Phase 2 study in CLL will evaluate MOR208 in combination with lenalidomide.
Wednesday, December 11, 2013
MorphoSys Strengthens European Patent Position on Anti-CD19 Cancer Program MOR208
New patent has a scheduled expiry date in 2027.
Tuesday, December 03, 2013
MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208
New patent covers the antibody's protein sequence.
Tuesday, October 22, 2013
MorphoSys Collaborator to Start Pivotal Study with Bimagrumab
MorphoSys to receive clinical milestone payment.
Thursday, October 03, 2013
MorphoSys Receives Two Phase 2 Milestone Payments from Janssen
MOR202 in phase 1/2a trial for multiple myeloma.
Tuesday, September 17, 2013
MorphoSys Closes on the Alliance with Celgene for MOR202 and Increases Financial Guidance
Celgene acquires 3.4 % equity stake via a capital increase.
Monday, August 12, 2013
MorphoSys AG Reports Results for the First Six Months of 2013
Results strongly impacted by MOR103 licensing agreement with GSK.
Monday, August 05, 2013
MorphoSys and Celgene Create Strategic Alliance
Development of novel therapeutic antibody approach being evaluated in clinical trials for patients with multiple myeloma.
Thursday, June 27, 2013
MorphoSys Signs Global License Agreement with GSK
MorphoSys to receive committed and success-based payments of up to EUR 445 million and double-digit royalties on net sales.
Tuesday, June 04, 2013
MorphoSys Initiates Phase 2 Study of MOR208 in NHL
Company has dosed the first patient in Phase 2 clinical trial of anti-CD19 antibody.
Monday, May 13, 2013
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!